查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1870508

膽紅素血液檢測市場按檢測類型、方法、最終用戶和應用分類 - 全球預測 2025-2032

Bilirubin Blood Test Market by Test Type, Method, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，膽紅素血液檢測市場將成長至 28 億美元，複合年成長率為 11.15%。

關鍵市場統計數據
基準年 2024 12億美元
預計年份：2025年 13.4億美元
預測年份 2032 28億美元
複合年成長率 (%) 11.15%

本文簡要概述了膽紅素檢測在新生兒科、肝病科實踐和診斷檢測流程中的臨床重要性和不斷發展的作用。

膽紅素血液檢測在臨床診斷、新生兒篩檢和肝病監測中發揮核心作用，將實驗室科學與第一線患者照護緊密聯繫起來。作為新生兒至成人肝功能和溶血過程的關鍵指標，此檢測持續為診斷決策提供資訊、監測治療效果並指南緊急臨床決策。隨著技術的進步，分析方法日益多樣化，能夠在保持檢測診斷價值的同時，更精確地區分結合膽紅素和非結合膽紅素，從而在照護現場環境中實現更有效率的工作流程整合。

調查方法創新、檢測分散化和臨床指引更新對膽紅素檢測診斷路徑和實驗室決策的影響

隨著技術的進步、診斷的去中心化以及與電子健康生態系統的融合，膽紅素檢測領域正經歷變革性的轉變。曾經由中心實驗室主導的分析平台正日益被更貼近患者的檢測方式所補充，從而實現早期療育和更簡化的診療路徑。同時，先進的層析法和高解析度分析技術提高了檢測的特異性，增強了臨床醫生區分複雜肝源性和溶血性病因的能力。

評估2025年美國關稅變化對採購、製造夥伴關係和臨床試驗連續性造成的營運和供應鏈影響

美國2025年實施的新關稅和貿易政策調整，對膽紅素檢測相關診斷劑、儀器零件和耗材的全球供應鏈產生了實際的影響。採購團隊和製造商正在重新審視其籌資策略，以降低投入成本的波動，尤其專注於特殊零件和單一來源零件。為此，眾多相關人員正在推動供應商多元化，並建立區域分銷網路，以保障供應的連續性並維持臨床檢測能力。

可操作的細分分析，將測試類型、分析方法、最終用戶需求和詳細的臨床應用進行映射，為採購和臨床路徑決策提供資訊。

基於細分市場的洞察揭示了不同分析類別、臨床環境和臨床適應症的顯著趨勢，這對檢測方法的應用模式和投資重點具有重要意義。從檢測類型來看，診斷領域仍依賴直接膽紅素、間接膽紅素和總膽紅素的檢測來解決不同的臨床問題。當懷疑存在結合型高膽紅素血症時，直接膽紅素檢測是首選；而間接膽紅素和總膽紅素檢測對於溶血性疾病和新生兒黃疸的篩檢和監測至關重要。因此，實驗室正在調整其工作流程，以確保能夠根據患者的症狀和臨床醫囑提供合適的檢測項目並準確報告結果。

美洲、歐洲、中東和非洲以及亞太地區的區域性需求和差異化需求模式正在推動客製化產品和服務策略的發展。

區域趨勢正在影響膽紅素檢測領域中相關人員的需求模式和策略重點。在美洲，成熟的臨床基礎設施和完善的新生兒篩檢計畫支持就地檢驗和高通量實驗室解決方案的穩定需求。醫療系統正優先考慮整合報告和數據互通性，推動對能夠與電子健康記錄 (EHR) 和實驗室資訊管理系統 (LIMS) 無縫整合的平台進行投資。

儀器製造商、試劑供應商和服務夥伴之間的競爭與合作模式塑造了產品差異化和客戶維繫策略。

膽紅素檢測領域的競爭動態呈現出技術差異化、卓越服務和策略夥伴關係的特徵。為了贏得高通量臨床實驗室和醫院系統的信任，主要企業致力於透過整合儀器可靠性、試劑一致性和整合軟體，最佳化整個工作流程的價值。創新路徑強調使用者友善的介面、簡化的校準流程和遠距離診斷功能，從而減少停機時間並簡化複雜儀器的維護。

為產業領導者提供實際的策略行動，以加強供應鏈、擴展模組化測試平台，並透過教育和夥伴關係加速臨床應用。

為了維持臨床相關性和商業性永續性，產業領導者應優先考慮多管齊下的方法，以平衡技術投資、供應鏈韌性和相關人員。首先，投資於支援高通量實驗室工作流程和床邊檢測的模組化平台，能夠幫助機構最佳化設備利用率，同時滿足更廣泛的臨床應用需求。這些平台的設計應便於升級，並能與實驗室資訊系統互通性，從而減少整合阻力。

一個嚴謹的混合方法研究框架，結合專家訪談、臨床文獻和監管分析，旨在產生可操作的診斷和商業性見解。

本執行執行摘要的研究採用了混合方法，整合了技術、臨床和商業性的見解。主要研究包括對不同機構中參與膽紅素檢測的實驗室主任、臨床病理學家、採購經理和技術專家進行結構化訪談。透過這些訪談所獲得的關於方法選擇、操作限制和臨床決策標準的質性見解，輔以二手資料進行三角驗證。

將長期存在的臨床角色與不斷發展的技術、供應鏈和區域趨勢相結合，這些趨勢將塑造未來的診斷和營運重點。

現代膽紅素檢測格局的特點在於其兼顧了持久的臨床效用和動態的技術創新。直接膽紅素、間接膽紅素和總膽紅素的核心檢測方法仍然是重要的臨床工具，而多樣化的調查方法則在臨床需要時為提高診斷準確性提供了途徑。檢測的去中心化和照護現場能力的提升正在重塑結果報告的預期，而中心實驗室在確診檢測和高解析度分析中仍然發揮著至關重要的作用。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 新生兒加護病房迅速採用照護現場膽紅素分析儀進行黃疸即時評估
  • 臨床實驗室部署高通量自動化膽紅素檢測平台，以滿足日益成長的篩檢需求。
  • 非侵入性經皮膽紅素監測儀的出現可減少新生兒的血液採樣次數
  • 透過整合數位資料管理系統和膽紅素檢測工作流程，實現即時病患監測和分析
  • 液相層析法聯用技術擴大用於準確定量分析膽紅素異構體，從而診斷肝臟疾病。
  • 診斷公司與遠端醫療服務提供者合作，實現遠距膽紅素監測和諮詢

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 膽紅素血液檢測市場（依檢測類型分類）

  • 直接型
  • 間接
  • 總膽紅素

9. 依檢測方法分類的膽紅素血液檢測市場

  • 層析法
  • 重氮法
  • 酵素法
  • HPLC
  • 光強度

第10章 依最終用戶分類的膽紅素血液檢測市場

  • 學術和研究機構
  • 臨床實驗室
  • 診斷中心
  • 醫院
  • 即時檢測

第11章 依應用分類的膽紅素血液檢測市場

  • 肝病
    • 酒精性肝臟疾病
    • 肝硬化
    • 病毒性肝炎
      • 甲型肝炎
      • B型肝炎
      • C型肝炎
  • 新生兒篩檢

第12章 各地區膽紅素血液檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 膽紅素血液檢測市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國膽紅素血液檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Siemens Healthineers AG
    • Danaher Corporation
    • Thermo Fisher Scientific Inc
    • Sysmex Corporation
    • bioMerieux SA
    • Ortho Clinical Diagnostics Inc
    • Mindray Medical International Limited
    • DiaSorin SpA
Product Code: MRR-1A1A064C0149

The Bilirubin Blood Test Market is projected to grow by USD 2.80 billion at a CAGR of 11.15% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.20 billion
Estimated Year [2025] USD 1.34 billion
Forecast Year [2032] USD 2.80 billion
CAGR (%) 11.15%

A concise orientation to the clinical importance and evolving role of bilirubin testing across neonatal care, hepatology practice, and diagnostic laboratory workflows

Bilirubin blood testing occupies a central role in clinical diagnostics, neonatal screening, and hepatology research, bridging laboratory science and frontline patient care. The assay remains a primary indicator of hepatic function and hemolytic processes, informing diagnosis, monitoring therapeutic response, and guiding urgent clinical decisions in newborns and adults. As technologies evolve, the test's diagnostic value is preserved while analytical approaches diversify, enabling more precise differentiation between conjugated and unconjugated bilirubin and offering improved workflow integration across laboratory and point-of-care environments.

This executive summary synthesizes the contemporary landscape for bilirubin testing by focusing on technical modalities, clinical applications, end-user dynamics, and regulatory influences that shape adoption. The narrative emphasizes how methodological innovation, shifting care delivery models, and supply chain considerations interact to produce measurable changes in laboratory practice. It also highlights the practical implications for stakeholders ranging from clinical laboratory directors and hospital procurement teams to reagent manufacturers and research institutions.

Moving from context to actionable insight, the summary clarifies where clinical demand is most pronounced, which analytical methods are gaining traction, and how institutional settings influence procurement choices. By balancing technical specificity with strategic perspective, the introduction prepares decision-makers to prioritize investments in instrumentation, training, and partnerships that align with evolving clinical and operational requirements.

How methodological innovation, decentralization of testing, and clinical guideline updates are reshaping diagnostic pathways and laboratory decision-making for bilirubin assays

The landscape for bilirubin testing is undergoing transformative shifts driven by technological refinement, decentralization of diagnostics, and integration with electronic health ecosystems. Analytical platforms that once were the exclusive domain of centralized laboratories are increasingly complemented by near-patient testing options, enabling earlier intervention and streamlined care pathways. Concurrently, advanced chromatographic and high-resolution analytical techniques are enhancing specificity, thereby improving clinicians' ability to distinguish complex hepatic and hemolytic etiologies.

At the same time, methodological convergence is evident: spectrophotometric and enzymatic assays maintain prominence for routine screening due to throughput and cost-effectiveness, while chromatographic and HPLC approaches serve confirmatory and research-grade roles. This duality supports a layered diagnostic strategy in which rapid screening informs immediate clinical action and higher-resolution methods refine diagnosis and treatment planning. In parallel, automation and laboratory information system integration are reducing manual error, accelerating turnaround, and supporting standardized reporting across institutions.

Regulatory and clinical guideline updates have further catalyzed change by clarifying thresholds for intervention, particularly in neonatal care, and by encouraging harmonized reporting practices for conjugated versus unconjugated bilirubin. Taken together, these shifts are producing a more nuanced diagnostic ecosystem in which method choice is increasingly aligned with clinical context, operational capacity, and desired granularity of results.

Assessing the operational and supply chain ramifications of United States tariff changes in 2025 on procurement, manufacturing partnerships, and clinical testing continuity

The introduction of new tariff measures and trade policy adjustments in the United States during 2025 has introduced tangible downstream effects across the global supply chain for diagnostic reagents, instrumentation components, and consumables relevant to bilirubin testing. Procurement teams and manufacturers are reassessing sourcing strategies to mitigate input cost volatility, with a particular focus on components that are specialized or single-source. In response, several stakeholders have pursued diversified supplier portfolios and regional distribution arrangements to protect continuity of supply and maintain clinical testing capacity.

Beyond procurement tactics, tariff-driven cost pressures are prompting reassessment of total cost of ownership for clinical instrumentation. Healthcare providers and laboratory networks are increasingly evaluating service contract terms, reagent rental options, and extended warranties as mechanisms to smooth capital expenditure. At the same time, vendor teams are refining product bundling and localized support to retain competitiveness in environments where import-related expenses influence purchasing decisions.

Moreover, the policy environment has accelerated interest in domestic manufacturing and regional supply resilience. This trend is not limited to device makers but extends to chemical reagents and calibration materials that underpin assay performance. Consequently, regulatory compliance and quality assurance processes are being revisited as firms establish new manufacturing relationships or requalify alternative suppliers. Overall, the tariff landscape in 2025 has underscored the strategic importance of supply chain agility, contractual flexibility, and proactive stakeholder engagement to preserve testing continuity and cost predictability.

Actionable segmentation insights that map test types, analytical methods, end-user needs, and detailed clinical applications to inform procurement and clinical pathways

Segmentation-based insights reveal differentiated dynamics across analytical classes, care settings, and clinical indications that materially influence adoption patterns and investment priorities. When viewed through the prism of test type, the diagnostic community continues to rely on direct, indirect, and total bilirubin measures to address distinct clinical questions. Direct bilirubin assessments are prioritized when conjugated hyperbilirubinemia is suspected, whereas indirect and total bilirubin metrics remain essential for screening and monitoring hemolytic conditions and neonatal jaundice. Consequently, laboratories calibrate their workflows to ensure that the appropriate subset of tests is available and accurately reported based on presenting symptoms and clinician directives.

Considering methodological segmentation, chromatographic, diazo, enzymatic, HPLC, and spectrophotometry approaches each occupy defined roles. Chromatographic and HPLC techniques are typically leveraged for analytical specificity and confirmatory testing, enabling separation and precise quantification of bilirubin species. The diazo reaction and enzymatic assays provide robust, cost-effective solutions for high-throughput screening, while spectrophotometry delivers scalable options for routine panels and smaller laboratory settings. Method selection is frequently a function of the clinical question, available instrumentation, throughput demands, and the need for traceable calibration.

End-user segmentation further clarifies market dynamics, as academic and research institutes pursue high-resolution methods for investigative work while clinical laboratories and diagnostic centers emphasize throughput and reproducibility. Hospitals require integrated solutions that support inpatient workflows and urgent care, and point-of-care testing continues to expand in settings where rapid turnaround drives clinical decisions. These distinctions inform procurement cycles, service-level expectations, and training requirements.

Lastly, application-based segmentation underscores clinical priorities with hepatic disorders and newborn screening as focal areas. Within hepatic disorders, attention is concentrated on alcoholic liver disease, cirrhosis, and viral hepatitis, with viral hepatitis further delineated into hepatitis A, hepatitis B, and hepatitis C. These clinical subdivisions drive differential test utilization, with monitoring protocols and confirmatory testing pathways tailored to disease progression, treatment response, and public health screening initiatives. Cumulatively, segmentation analysis highlights the necessity of offering a spectrum of technological solutions and service models to meet heterogeneous clinical and operational demands.

Regional imperatives and differentiated demand patterns across the Americas, Europe Middle East & Africa, and Asia Pacific that drive tailored product and service strategies

Regional dynamics are shaping both demand patterns and strategic priorities for stakeholders operating in the bilirubin testing space. In the Americas, clinical infrastructure maturity and well-established neonatal screening programs sustain consistent demand for both point-of-care and high-throughput laboratory solutions. Healthcare systems emphasize integrated reporting and data interoperability, prompting investment in platforms that seamlessly interface with electronic health records and laboratory information management systems.

In the Europe, Middle East & Africa region, heterogeneity across markets necessitates flexible product strategies. High-capacity tertiary centers and centralized laboratories in Western Europe favor advanced chromatographic and HPLC approaches for specialized testing, while resource-constrained settings across the broader region prioritize affordability and robustness. Regulatory frameworks and reimbursement policies further influence adoption, incentivizing solutions that balance diagnostic accuracy with cost containment.

Across Asia-Pacific, rapid expansion of healthcare access and growing investments in maternal and child health programs are driving heightened uptake of newborn screening services and point-of-care applications. The region demonstrates a mix of cutting-edge research hubs and decentralized primary care environments, creating a dual demand for high-resolution instrumentation and portable, easy-to-use assays. Supply chain considerations and local manufacturing capabilities also play a pivotal role in shaping procurement decisions across these diverse markets.

Taken together, regional insights underscore that a one-size-fits-all commercial or clinical approach is suboptimal; instead, success depends on tailoring product features, service models, and market engagement strategies to distinct regional priorities and institutional capabilities.

Competitive and collaborative patterns among instrument manufacturers, reagent providers, and service partners shaping product differentiation and customer retention strategies

Competitive dynamics in the bilirubin testing ecosystem are characterized by a blend of technological differentiation, service excellence, and strategic partnerships. Leading firms focus on optimizing total workflow value-combining instrumentation reliability, reagent consistency, and integrated software-to earn trust from high-volume clinical laboratories and hospital systems. Innovation pathways emphasize user-friendly interfaces, streamlined calibration, and remote diagnostics capabilities that reduce downtime and simplify maintenance for complex equipment.

Partnerships between diagnostic manufacturers, reagent suppliers, and clinical networks are increasingly important, as these collaborations enable bundled offerings and shared responsibility for performance standards. At the same time, entrants that concentrate on point-of-care innovations are reshaping expectations for rapid result delivery and ease of use, compelling established vendors to expand their portfolios or pursue targeted acquisitions. Service models that include training, remote monitoring, and flexible commercial terms are proving decisive in procurement decisions, particularly among hospital systems and centralized laboratories.

Intellectual property and assay optimization remain central differentiators, particularly for methods that require specialized reagents or proprietary calibration materials. Meanwhile, firms that offer transparent validation data, clinical performance studies, and strong regulatory support tend to achieve higher acceptance in conservative clinical settings. Overall, the competitive landscape rewards companies that combine technical rigor with responsive customer support and agile supply chain management.

Practical strategic actions for industry leaders to fortify supply chains, expand modular testing platforms, and accelerate clinical adoption through education and partnerships

Industry leaders should prioritize a multi-pronged approach that balances technological investment, supply chain resilience, and stakeholder engagement to maintain clinical relevance and commercial sustainability. First, investment in modular platforms that support both high-throughput laboratory workflows and near-patient testing will enable organizations to capture a broader range of clinical use cases while optimizing equipment utilization. These platforms should be designed for straightforward upgradeability and interoperability with laboratory information systems to reduce integration friction.

Second, manufacturers and procurement teams must deepen supply chain visibility by qualifying multiple suppliers for critical reagents and components, establishing regional inventory buffers, and negotiating flexible contractual terms. These measures reduce vulnerability to policy shifts and logistical disruptions while preserving consistent assay performance. Third, vendors and clinical leaders should collaborate to develop education and training programs that reinforce correct assay usage, interpretation of conjugated versus unconjugated results, and best practices for neonatal screening protocols.

Fourth, organizations should adopt outcome-focused validation studies that demonstrate clinical utility across distinct end users and applications, thereby supporting adoption among conservative institutions. Finally, stakeholders should explore strategic partnerships and localized manufacturing options where appropriate to strengthen market access and compliance alignment. By implementing these actions in a coordinated manner, industry participants can enhance resilience, accelerate adoption, and improve patient care outcomes.

A rigorous mixed-methods research framework combining expert interviews, clinical literature, and regulatory analysis to produce actionable diagnostic and commercial insights

The research underpinning this executive summary employed a mixed-methods approach to synthesize technical, clinical, and commercial insights. Primary research included structured interviews with laboratory directors, clinical pathologists, procurement managers, and technical specialists involved in bilirubin testing across diverse institutional settings. These conversations provided qualitative context on method selection, operational constraints, and clinical decision thresholds, which were further triangulated with secondary sources.

Secondary research encompassed peer-reviewed literature, clinical guidelines, regulatory documents, and publicly available technical white papers that describe assay principles and performance characteristics. Method-specific validation studies and comparative analyses were consulted to understand analytical strengths and limitations of chromatographic, diazo, enzymatic, HPLC, and spectrophotometric approaches. Regional policy reviews and supply chain analyses informed assessment of procurement trends and tariff impacts.

Data synthesis prioritized methodological transparency and reproducibility. Insights were cross-validated through multiple expert interviews and alignment with contemporary clinical practice recommendations. Limitations were acknowledged where primary data access was constrained, and where appropriate, recommendations were framed to reflect variability in institutional capabilities and regional contexts. This methodological rigor ensures that the findings are actionable and relevant for decision-makers seeking to align diagnostic investments with clinical and operational priorities.

Synthesis of enduring clinical roles and evolving technological, supply chain, and regional dynamics that determine future diagnostic and operational priorities

The contemporary bilirubin testing landscape is defined by a balance between enduring clinical utility and dynamic technological change. Core assays for direct, indirect, and total bilirubin remain essential clinical tools, while methodological diversification offers pathways to greater diagnostic precision where clinically warranted. Decentralization of testing and expansion of point-of-care capabilities are reshaping turnaround expectations, yet centralized laboratories continue to play a critical role for confirmatory and high-resolution analysis.

Supply chain pressures and trade policy shifts have heightened the strategic importance of diversified sourcing, regional partnerships, and flexible commercial models. At the same time, regional heterogeneity in healthcare infrastructure and regulatory environments requires tailored market engagement and product adaptation. Competitive advantage accrues to organizations that combine technical excellence with robust service models, transparent validation, and strong customer training programs.

In sum, the sector is poised for incremental innovation that reinforces diagnostic accuracy and operational efficiency. Stakeholders who align platform flexibility, supply chain resilience, and clinical evidence generation will be best positioned to deliver sustained value to healthcare providers and patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid growth of point-of-care bilirubin analyzers in neonatal intensive care units for immediate jaundice assessment
  • 5.2. Implementation of high-throughput automated bilirubin testing platforms in clinical labs to meet rising screening demands
  • 5.3. Emergence of noninvasive transcutaneous bilirubinometry devices to reduce newborn blood draw procedures
  • 5.4. Integration of digital data management systems with bilirubin test workflows for real-time patient monitoring and analytics
  • 5.5. Increased use of liquid chromatography-mass spectrometry methods for precise quantification of bilirubin isomers in liver disease diagnosis
  • 5.6. Collaborations between diagnostics companies and telehealth providers to enable remote bilirubin monitoring and consultation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bilirubin Blood Test Market, by Test Type

  • 8.1. Direct
  • 8.2. Indirect
  • 8.3. Total

9. Bilirubin Blood Test Market, by Method

  • 9.1. Chromatographic
  • 9.2. Diazo
  • 9.3. Enzymatic
  • 9.4. HPLC
  • 9.5. Spectrophotometry

10. Bilirubin Blood Test Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Clinical Laboratories
  • 10.3. Diagnostic Centers
  • 10.4. Hospitals
  • 10.5. Point Of Care Testing

11. Bilirubin Blood Test Market, by Application

  • 11.1. Hepatic Disorders
    • 11.1.1. Alcoholic Liver Disease
    • 11.1.2. Cirrhosis
    • 11.1.3. Viral Hepatitis
      • 11.1.3.1. Hepatitis A
      • 11.1.3.2. Hepatitis B
      • 11.1.3.3. Hepatitis C
  • 11.2. Newborn Screening

12. Bilirubin Blood Test Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bilirubin Blood Test Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bilirubin Blood Test Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. F. Hoffmann-La Roche Ltd
    • 15.3.2. Abbott Laboratories
    • 15.3.3. Siemens Healthineers AG
    • 15.3.4. Danaher Corporation
    • 15.3.5. Thermo Fisher Scientific Inc
    • 15.3.6. Sysmex Corporation
    • 15.3.7. bioMerieux SA
    • 15.3.8. Ortho Clinical Diagnostics Inc
    • 15.3.9. Mindray Medical International Limited
    • 15.3.10. DiaSorin S.p.A

LIST OF FIGURES

  • FIGURE 1. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BILIRUBIN BLOOD TEST MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BILIRUBIN BLOOD TEST MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BILIRUBIN BLOOD TEST MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIRECT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIRECT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIRECT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIRECT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIRECT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIRECT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY INDIRECT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY INDIRECT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY INDIRECT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY INDIRECT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY INDIRECT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY INDIRECT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TOTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TOTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TOTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TOTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TOTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TOTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CHROMATOGRAPHIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CHROMATOGRAPHIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CHROMATOGRAPHIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CHROMATOGRAPHIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CHROMATOGRAPHIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CHROMATOGRAPHIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAZO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAZO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAZO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAZO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAZO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAZO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ENZYMATIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ENZYMATIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ENZYMATIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ENZYMATIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ENZYMATIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ENZYMATIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HPLC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HPLC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HPLC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HPLC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HPLC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HPLC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY SPECTROPHOTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY SPECTROPHOTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY SPECTROPHOTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY SPECTROPHOTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY SPECTROPHOTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY SPECTROPHOTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CIRRHOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CIRRHOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CIRRHOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CIRRHOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CIRRHOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CIRRHOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS A, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS A, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS A, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS C, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS C, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2032 (USD MILLION)
  • TABLE 273. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 278. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 279. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 284. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 285. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
  • TABLE 286. GCC BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 306. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 307. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 311. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 312. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 313. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
  • TABLE 314. BRICS BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2032 (USD MILLION)
  • TABLE 315. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 320. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 321. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 324. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 325. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 326. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 327. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
  • TABLE 328. G7 BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2032 (USD MILLION)
  • TABLE 329. NATO BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 330. NATO BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 331. NATO BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. NATO BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. NATO BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 334. NATO BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 335. NATO BILIRUBIN BLO